Laminated Tubes for Pharmaceuticals Market to Reach CAGR 7.20% by 2031 Top 20 Company Globally

Laminated tubes are flexible, multi-layer packaging tubes made by laminating thin polymer films (with or without an aluminum barrier) to form a lightweight, high-barrier sleeve that is heat-sealed at one end, filled, and sealed/closed with a cap or nozzle; in pharmaceutical use they package ointments, dermatological creams, antibiotic gels, dental pastes, ophthalmic ointments and some topical drug-delivery products where dose integrity, shelf-life, chemical compatibility and tamper evidence matter. Compared with mono-polymer squeeze tubes and aluminium collapsible tubes, laminated tubes (plastic barrier laminate PBL and aluminium barrier laminate ABL) offer a compromise of barrier, printability and cost, and can be engineered into pharma-grade contact layers, child-resistant nozzles and sterile-ready formats that meet regulatory contact-material and extractables/impurities requirements. Manufacturers supply tubes in sizes ranging from small ophthalmic/dermal 35 g mini-tubes to 100+ ml pharmaceutical dispensers; the product sits at the intersection of rigid regulation (pharma contact layers), decorative/brand requirements and the practical needs of hospital and retail dispensing.

The laminated-tube for pharmaceuticals estimate of roughly USD 252 million in 2024. Applying a slightly faster adoption rate for pharma, this pharmaceutical laminated-tube subsegment is projected to grow at a CAGR of 7.2% to 2031, producing an approximate market around USD 410 million by 2031. Unit pricing for pharma laminated tubes for pharmaceuticals varies sharply by capacity, barrier construction, decoration, caps, and order quantity/qualification. Average selling price (ASP) of USD 0.44 per tube in 2024 , the USD 252 million revenue implies an implied global shipment of 573 million pharmaceutical laminated tubes in 2024.
Latest Trends and Technological Developments
The laminated-tube sector for pharmaceuticals is being reshaped by two dominant forces: material circularity and pharma contact-layer innovation, and by format/functional improvements (child-resistant micro-nozzles, sterile mini-tubes and mono-material recycle-ready laminates). On June 2024 Hoffmann Neopac won a Tube Council award for a smallest child-resistant polyfoil tube prototype, reflecting product miniaturisation and safety features being engineered specifically with pharma/dental use cases in mind. On the sustainability front, Albéa announced scaled production of its Greenleaf recycle-ready plastic laminate web at its Brampton, Ontario site (publicly reported in late 2024 / early 2025), a commercial move aimed at enabling single-material laminated constructions suitable for mechanical recycling while retaining pharma-grade contact layers. In early 2025 EPL (formerly Essel Propack) continued to publicize capacity expansions and investor disclosures (EPL investor presentation, August 2025) that underline the industrys volume and qualification investments to serve pharma customers with validated lines. In parallel, Neopac and other suppliers introduced aluminum-free mono-material barrier (MMB/Polyfoil) mini-tubes for ophthalmic and dental pharma applications at CPhI-Milan in 20242025, offering a path to reduce ABL dependence while preserving barrier and regulatory compliance. Those dated developments Hoffmann Neopac (June 22024), Albéa Greenleaf production (announced ~20242025), EPL investor updates (Aug 5, 2025), and Neopac MMB rollouts (20242025) represent the most material, recent shifts affecting pharma laminated tubes: migration to recycle-ready laminates, feature innovation for safety/sterility, and capacity/qualification investments to meet pharma quality systems.
Asia Pacific is the largest manufacturing hub and a rapidly expanding consumption region for pharmaceutical laminated tubes. India and China are major global production centers India houses EPLs large manufacturing footprint and Chinas OEM base supplies high volumes at competitive ASPs while Japan, Korea and parts of Southeast Asia account for disproportionate high-spec pharma demand (premium ABL tubes and speciality closures). Regional drivers include strong OTC topical markets, growing dermatology product launches originating in Asia, expanding domestic pharmaceutical formulation capabilities that prefer locally qualified packaging, and cost advantages for high-volume laminates produced in Asia. Several global laminates and tube manufacturers have either expanded Asian production or localized laminate web making (for example Albéas Greenleaf expansion for North American/Asia sourcing) to shorten qualification cycles and reduce landed cost for pharma customers. This Asia manufacturing density also compresses lead times for pharmaceutical companies seeking global supply continuity and faster registration support.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/sample/4947512

Laminated Tubes for Pharmaceuticals by Type:
Plastic Barrier Laminate (PBL) Tubes

Aluminum Barrier Laminate (ABL) Tubes

Laminated Tubes for Pharmaceuticals by Application:
Ointments

Gels

Others

Global Top 20 Key Companies in the Laminated Tubes for Pharmaceuticals Market
Essel Propack

Colgate Palmolive

Albea

SUNA

Sree rama

Scandolara

Kyodo Printing

Kimpai

Zalesi

Noepac

Tuboplast

Toppan

BeautyStar

Rego

IntraPac

DNP

Plastuni

Montebello

Plastube

Berry

Regional Insights
ASEAN is a high-growth market for pharma laminated tubes as regional pharma production, topical OTC brands and dermocosmetic lines expand. Indonesia, as ASEANs largest population market, shows particular traction: local pharma and consumer health manufacturers increasingly specify laminated tubes for dermatological and topical OTC formulations because they combine brandability with cost efficiency and acceptable barrier performance. Procurement patterns in Indonesia and neighboring ASEAN countries typically bifurcate hospital and export-oriented pharma companies buy higher-spec ABL tubes and child-resistant closures, while domestic OTC and SMEs buy large volumes of low-cost PE-laminate mini-tubes and pre-decorated PBL formats. Regional supply is supplied by a mix of local OEMs and international suppliers (EPL, Neopac, Albéa, Huhtamäki and Chinese tube makers) that operate local distribution and small-batch decoration to service ASEANs fragmented buyer base. Policy and sustainability programs in some ASEAN countries are beginning to nudge buyers toward recyclable solutions; suppliers that can offer validated pharma contact layers in recyclable formats will have an advantage for export-oriented pharma customers in Indonesia and Vietnam.
The laminated-tube for pharma niche faces four principal challenges. First, regulatory compliance and qualification cycles: pharmaceutical customers require validated contact layers, extractables/leachables data, and change-control documentation qualification timelines are long and discourage frequent supplier swaps. Second, circularity and recycling constraints: many ABL (aluminium barrier) laminates are hard to recycle; the industry faces pressure from brand owners and regulators to introduce mono-material or recycle-ready laminates without compromising barrier or regulatory suitability for drugs. Third, pricing pressure from low-cost Asian OEMs competes directly with premium European/Japanese suppliers this compresses margins when projects are competed purely on cost rather than qualification value. Fourth, fragmentation of cap/closure standards (child-resistant, tamper-evident, dosing tips) adds SKU complexity and inventory costs for suppliers, especially when small-batch pharma clients require custom cap solutions. These structural frictions appear in supplier roadmaps, trade-association guidance and procurement briefs across pharma packaging tenders.

Winning suppliers will combine three capabilities: proven pharma-grade contact layers and extractables testing (to shorten customer qualification), scalable low-cost manufacturing with localized decoration/secondary packaging for regional markets, and credible sustainability roadmaps (recycle-ready laminates, take-back pilots or industrial recycling partnerships such as Neopacs Saperatec agreement). For global pharmaceutical customers, single-source qualified suppliers with multiple regional plants reduce regulatory risk and speed time to market; for regional OTC/dermocosmetic brands, agile decoration and short lead times are the priority. From a product perspective, mono-material barrier mini-tubes and child-resistant micro-nozzle options represent high-value innovation pockets where suppliers can command premium pricing. For suppliers targeting ASEAN, offering bundled services artwork management, small-batch serialization and regulatory data packs can differentiate in procurement rounds dominated by tendered price comparisons.

Product Models
Laminated tubes for pharmaceuticals are widely used packaging solutions that combine durability, barrier protection, and patient convenience. They help protect sensitive pharmaceutical formulations from moisture, oxygen, and contamination while offering easy dispensing.
Plastic Barrier Laminate (PBL) tubes which use multiple plastic layers for excellent aesthetics and flexibility. Notable products include:
Essel Propack PBL Pharma Tube Essel Propack (EPL Limited): High-quality laminated tube with strong barrier and printability for pharma gels.
Huhtamaki PBL Tube Huhtamaki Group: Durable plastic laminate tubes for ointments and topical medications.
Montebello PBL Pharma Tube Montebello Packaging: Offers flexibility and smooth finish for pharmaceutical creams.
Berry Global PBL Tube Berry Global Inc.: Multi-layer plastic tube designed for drug formulations requiring protection.
Tuboplast PBL Tube Albea Group (Tuboplast Hispania): Elegant laminated plastic tubes designed for dermatology and pharma use.
Aluminum Barrier Laminate (ABL) tubes which include an aluminum layer for superior barrier protection against light, oxygen, and moisture. Examples include:
Essel Propack ABL Tube Essel Propack (EPL Limited): Aluminum laminate with strong barrier, ideal for semi-solid pharma formulations.
Huhtamaki ABL Tube Huhtamaki Group: Combines aluminum foil with laminate layers for superior protection.
Albea ABL Tube Albea Group: Lightweight laminated tube with aluminum foil barrier for extended shelf life.
Neopac Polyfoil ABL Tube Hoffmann Neopac AG: Enhanced barrier tube for high-value and sensitive pharma formulations.
Amcor ABL Tube Amcor Flexibles: Strong laminated tube with aluminum foil core for superior moisture resistance.
Pharmaceutical laminated tubes are a durable packaging category that blends regulatory complexity with high unit volumes, brand importance and growing sustainability pressure. Using a reconciled approach midpoint global laminated-tube market we estimate a 2024 pharma laminated-tube market of USD 252 million, with an estimated CAGR 7.20% to 2031 and an implied 573 million tubes shipped in 2024 at an ASP of USD 0.44. Growth will be driven by OTC topical and dermatology product launches, expanding pharma production in Asia, product innovations that combine child safety and sterile miniaturisation, and supplier moves toward recycle-ready laminates while capacity and qualification investments by major players will be decisive in securing long multi-year pharma offtakes.

Investor Analysis
For investors the what is a recurring-volume, regulated packaging niche with attractive unit economics and high switching costs for established pharma customers. The how is by backing companies (or M&A targets) that combine validated pharma contact-layer testing, multiple regional plants (to shorten qualification and reduce logistics risk), and a credible sustainability route toward recycle-ready webs (which large global pharma buyers are beginning to demand). The why is that pharma contracts tend to be long and volume-predictable (multi-year offtakes for topical drug families and OTC relaunches), providing stable cash flow and the potential to upsell higher-margin features (child-resistant caps, sterile kits, decorated runs). Key investment due diligence should validate a targets extractables/leachables dossiers, regional certification footprint (FDA/EMA/PMDA supporting documents where required), customer concentration risk, and the suppliers roadmap for mono-material or MMB solutions that preserve barrier. Successful plays include equity stakes in vertically integrated tube houses, investments in regional contract converters that serve large pharma clusters in India/China/ASEAN, or minority positions in technology suppliers that enable recycling or novel child-resistant closures.
Request for Pre-Order Enquiry On This Report
https://www.qyresearch.com/customize/4947512
5 Reasons to Buy This Report
It reconciles multiple syndicated market estimates into a defensible 2024 base for pharmaceutical laminated tubes and a clear CAGR to 2031, allowing investors and procurement teams to model revenue and unit scenarios.
It translates dollars into units with a transparent ASP methodology and a wide sensitivity range, critical for capacity planning and capex decisions.
It documents dated, material industry moves that directly affect product strategy and buyer procurement.
It gives region-level go-to-market insight for Asia and ASEAN. enabling prioritisation of local assembly, decoration capacity and regulatory dossiers.
It profiles the leading players and strategic levers so M&A, supplier selection and joint-venture decisions can be executed quickly.
5 Key Questions Answered
What is the best-supported 2024 market size for laminated tubes used in pharmaceuticals and the reasonable CAGR to 2031?
What is the likely global shipment volume in 2024 given realistic ASP bands, and how sensitive is volume to changes in ASP and pack mix?
Which dated industry developments in 20242025 materially change supplier competitiveness capacity expansions?
How should suppliers and investors prioritise Asia and ASEAN markets in build-out, and what local capabilities matter most for pharma qualification?
Who are the top suppliers, what differentiates them and which capabilities drive premium pricing and stickier contracts?
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: key insights, key emerging trends, etc.
Chapter 3: Manufacturers competitive analysis, detailed analysis of the product manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 5 & 6: Sales, revenue of the product in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: The main points and conclusions of the report.

Contact Information:
Tel: +1 626 2952 442 (US) ; +
86-1082945717 (China)
+62 896 3769 3166 (Whatsapp)
Email: willyanto@qyresearch.com; global@qyresearch.com
Website: www.qyresearch.com

About QY Research
QY Research has established close partnerships with over 71,000 global leading players. With more than 20,000 industry experts worldwide, we maintain a strong global network to efficiently gather insights and raw data.
Our 36-step verification system ensures the reliability and quality of our data. With over 2 million reports, we have become the world's largest market report vendor. Our global database spans more than 2,000 sources and covers data from most countries, including import and export details.
We have partners in over 160 countries, providing comprehensive coverage of both sales and research networks. A 90% client return rate and long-term cooperation with key partners demonstrate the high level of service and quality QY Research delivers.
More than 30 IPOs and over 5,000 global media outlets and major corporations have used our data, solidifying QY Research as a global leader in data supply. We are committed to delivering services that exceed both client and societal expectations.

This release was published on openPR.